ND

Nikles Dhanraj Toshniwal

Active Director Designated Partner DIN 07443646
DIN 07443646 First appointment May 2016 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2016
Shareholding value β€’β€’β€’β€’ Premium profile

About Nikles Dhanraj Toshniwal

Data last updated:

Nikles Dhanraj Toshniwal is a Designated Partner at Maxcross Pharmaceutical Llp (since 2016). The company operates in Pharma.

DIN 07443646
Primary Designation Designated Partner
Industry Pharma
First Appointment 12 May 2016
Oldest Company Age 10 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner12 May 20162016Active

Board colleagues of Nikles Dhanraj Toshniwal

Directorship timeline

Open interactive timeline →
Maxcross Pharmaceutical Llp
Premium access

Shareholding and investment profile for Nikles Dhanraj Toshniwal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nikles Dhanraj Toshniwal

Nikles Dhanraj Toshniwal currently holds 1 directorship: Maxcross Pharmaceutical Llp (Designated Partner, since 12 May 2016).

Nikles Dhanraj Toshniwal was first appointed on 12 May 2016 as Designated Partner at Maxcross Pharmaceutical Llp.

The current boards of Nikles Dhanraj Toshniwal's companies include Kishor Chandrakant Swami (Maxcross Pharmaceutical Llp), Pawan Ramprasadji Mundada (Maxcross Pharmaceutical Llp), Ramesh Anantrao Bhosale (Maxcross Pharmaceutical Llp), Vishnudas Bajranglal Baheti (Maxcross Pharmaceutical Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available